Vycor Medical, Inc. (OTCQB: VYCO) released its financial results for the three and nine months ended September 30, 2026, in a Form 8-K filed on November 13, 2026. The company operates through two business units: Vycor Medical, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, and NovaVision, a division focused on vision rehabilitation therapies.

For the third quarter of 2026, the company reported total revenue of $414,895, a decrease of 19% compared to the same period in 2025. The Vycor Medical division generated $402,048 in revenue during the quarter, down 18% from the prior year. Conversely, the NovaVision division, which remains in development, reported revenue of $12,847, representing a 41% increase over the 2025 period.

Over the first nine months of 2026, total revenue was $1,291,699, a decrease of 11% compared to the 2025 period. Vycor Medical generated $1,243,713 in revenue during this timeframe, down 11% from the prior year, while NovaVision revenue increased 11% to $47,986.

On a GAAP basis, the company reported an operating profit of $27,424 for the third quarter of 2026 and $80,083 for the nine months ended September 30, 2026. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $43,011 for the third quarter and $125,751 for the nine months.

Regarding clinical activity, the company noted that four new peer-reviewed studies were published on the ViewSite Brain Access System in 2026, bringing the total number of published clinical papers to 54. The company highlighted a case study on a pediatric tumor case, a retrospective study comparing VBAS to traditional blade retractors, a study on minimally invasive suboccipital tubular resection, and a report on intracerebral hemorrhage evacuation in Japan.